Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and Absolute Bioavailability of AZD0780 in Healthy Men
NCT05817461Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of laropiprant in hypercholesterolemia, sponsored by AstraZeneca. Primary endpoints: Absolute bioavailability (F) - Part 1, Area under the curve from time 0 extrapolated to infinity and 16 more. Started Apr 2023; status: completed.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05817461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817461.